Toshida Katsuya, Itoh Shinji, Nakayama Yuki, Yugawa Kyohei, Ishikawa Takuma, Tsutsui Yuriko, Tomiyama Takahiro, Iseda Norifumi, Fujiyoshi Sunao, Motomura Takashi, Toshima Takeo, Iwasaki Takeshi, Oda Yoshinao, Yoshizumi Tomoharu
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Gastroenterological Surgery I, Hokkaido University Hospital, Sapporo, Japan.
Ann Surg Oncol. 2025 Jul 12. doi: 10.1245/s10434-025-17813-9.
Signal-regulatory protein alpha (SIRPα) has recently garnered attention for its role in the immune system, commonly referred to as the "don't eat me" signal. However, the relationship between SIRPα expression in tumor cells and prognosis in patients undergoing hepatectomy for intrahepatic cholangiocarcinoma (ICC) has been scarcely reported.
A total of 117 patients who underwent hepatectomy for ICC were enrolled in this study. Immunohistochemical staining was performed to evaluate SIRPα, programmed cell death-ligand 1 (PD-L1), and cluster of differentiation 8 (CD8). The relationships between SIRPα expression, clinicopathological characteristics, and patient outcomes were analyzed.
The macrophage-SIRPα-positive group exhibited a higher rate of lymph node metastasis (p = 0.0013). The tumor-cell-SIRPα-positive group showed lower carcinoembryonic antigen levels (p = 0.0068) and fewer cases of the perihilar type (p = 0.0165). In multivariate analysis, SIRPα positivity in tumor cells was identified as an independent prognostic factor for both disease-free survival (p = 0.0198) and overall survival (p = 0.0089). Notably, SIRPα positivity in tumor cells showed no significant correlation with PD-L1 expression or CD8-positive tumor-infiltrating T cells in ICC.
Our findings demonstrate that SIRPα expression in tumor cells is more critical than its expression in macrophages for predicting the prognosis of patients with ICC following hepatic resection.
信号调节蛋白α(SIRPα)最近因其在免疫系统中的作用而受到关注,通常被称为“别吃我”信号。然而,肿瘤细胞中SIRPα表达与肝内胆管癌(ICC)肝切除患者预后之间的关系鲜有报道。
本研究共纳入117例行ICC肝切除术的患者。采用免疫组织化学染色评估SIRPα、程序性细胞死亡配体1(PD-L1)和分化簇8(CD8)。分析SIRPα表达、临床病理特征与患者预后之间的关系。
巨噬细胞SIRPα阳性组淋巴结转移率较高(p = 0.0013)。肿瘤细胞SIRPα阳性组癌胚抗原水平较低(p = 0.0068),肝门周围型病例较少(p = 0.0165)。多因素分析显示,肿瘤细胞中SIRPα阳性是无病生存期(p = 0.0198)和总生存期(p = 0.0089)的独立预后因素。值得注意的是,肿瘤细胞中SIRPα阳性与ICC中PD-L1表达或CD8阳性肿瘤浸润性T细胞无显著相关性。
我们的研究结果表明,对于预测肝切除术后ICC患者的预后,肿瘤细胞中SIRPα的表达比其在巨噬细胞中的表达更为关键。